Hello
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from _____________ to _____________
Commission File Number:
(Exact Name of Registrant as Specified in its Charter)
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including area code: (
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
The |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
☒ |
|
Smaller reporting company |
|
||
Emerging growth company |
|
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
As of May 24, 2024, the registrant had
Table of Contents
|
|
Page |
PART I. |
1 |
|
|
|
|
Item 1. |
1 |
|
|
1 |
|
|
2 |
|
|
Condensed Consolidated Statements of Comprehensive Income (Loss) |
3 |
|
Condensed Consolidated Statements of Stockholders' Equity (Deficit) |
4 |
|
5 |
|
|
Notes to Unaudited Condensed Consolidated Financial Statements |
6 |
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
25 |
Item 3. |
33 |
|
Item 4. |
34 |
|
|
|
|
PART II. |
37 |
|
|
|
|
Item 1. |
37 |
|
Item 1A. |
37 |
|
Item 2. |
37 |
|
Item 3. |
37 |
|
Item 4. |
37 |
|
Item 5. |
37 |
|
Item 6. |
38 |
|
40 |
||
|
|
PART I—FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements (unaudited)
ASTRA SPACE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
(Unaudited)
|
|
March 31, |
|
|
December 31, |
|
||
ASSETS |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
|
|
$ |
|
||
Restricted cash |
|
|
|
|
|
|
||
Trade accounts receivable |
|
|
|
|
|
|
||
Inventories |
|
|
|
|
|
|
||
Prepaid and other current assets |
|
|
|
|
|
|
||
Total current assets |
|
|
|
|
|
|
||
Non-current assets: |
|
|
|
|
|
|
||
Property, plant and equipment, net |
|
|
|
|
|
|
||
Right-of-use asset |
|
|
|
|
|
|
||
Intangible assets, net |
|
|
|
|
|
|
||
Other non-current assets |
|
|
|
|
|
|
||
Total assets |
|
$ |
|
|
$ |
|
||
|
|
|
|
|
|
|
||
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
|
|
$ |
|
||
Operating lease obligation, current portion |
|
|
|
|
|
|
||
Contract liabilities, current portion |
|
|
|
|
|
|
||
Accrued expenses and other current liabilities |
|
|
|
|
|
|
||
Warrants to purchase common stock (1)(4) |
|
|
|
|
|
|
||
Convertible Notes (2)(3) |
|
|
|
|
|
|
||
Total current liabilities |
|
|
|
|
|
|
||
Non-current liabilities: |
|
|
|
|
|
|
||
Operating lease obligation, net of current portion |
|
|
|
|
|
|
||
Contract liabilities, net of current portion |
|
|
|
|
|
|
||
Other non-current liabilities |
|
|
|
|
|
|
||
Total liabilities |
|
|
|
|
|
|
||
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
||
STOCKHOLDERS’ DEFICIT |
|
|
|
|
|
|
||
Preferred stock, $ |
|
|
|
|
|
|
||
Class A common stock, $ |
|
|
|
|
|
|
||
Class B common stock, $ |
|
|
|
|
|
|
||
Additional paid in capital |
|
|
|
|
|
|
||
Accumulated other comprehensive loss |
|
|
|
|
|
|
||
Accumulated deficit |
|
|
( |
) |
|
|
( |
) |
Total stockholders’ deficit |
|
|
( |
) |
|
|
( |
) |
Total liabilities and stockholders’ deficit |
|
$ |
|
|
$ |
|
(1) Warrants to purchase common stock includes Company Warrants (the "Company Warrants") issued to our Chief Executive Officer (the "CEO") and our Chief Technology Officer (the "CTO") in conjunction with the Convertible Notes issued November 21, 2023. As of March 31, 2024, the fair values of the CEO's and CTO's Company Warrants were $
(2) The CEO and CTO hold Convertible Notes whose fair values were $
(3) An affiliate of a director held Convertible Notes with a fair value of $
(4) An affiliate of a director held Company Warrants with a fair value of $
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
1
ASTRA SPACE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share data)
(Unaudited)
|
|
Three Months Ended |
|
|||||
|
|
2024 |
|
|
2023 |
|
||
Revenues |
|
|
|
|
|
|
||
Launch services |
|
$ |
|
|
$ |
|
||
Space products |
|
|
|
|
|
|
||
Total revenues |
|
|
|
|
|
|
||
Cost of revenues |
|
|
|
|
|
|
||
Launch services |
|
|
|
|
|
|
||
Space products |
|
|
|
|
|
|
||
Total cost of revenues |
|
|
|
|
|
|
||
Gross profit (loss) |
|
|
|
|
|
|
||
Operating expenses: |
|
|
|
|
|
|
||
Research and development |
|
|
|
|
|
|
||
Sales and marketing |
|
|
|
|
|
|
||
General and administrative |
|
|
|
|
|
|
||
Gain on change in fair value of contingent consideration |
|
|
|
|
|
( |
) |
|
Total operating expenses |
|
|
|
|
|
|
||
Operating loss |
|
|
( |
) |
|
|
( |
) |
Interest income |
|
|
|
|
|
|
||
Other income, net |
|
|
|
|
|
|
||
Gain on change in fair value of Convertible Notes(1)(3) |
|
|
|
|
|
|
||
Gain on change in fair value of Warrants(2)(4) |
|
|
|
|
|
|
||
Income (loss) before taxes |
|
|
|
|
|
( |
) |
|
Income tax provision |
|
|
|
|
|
|
||
Net income (loss) |
|
$ |
|
|
$ |
( |
) |
|
|
|
|
|
|
|
|
||
Net loss per share: |
|
|
|
|
|
|
||
Weighted average number of shares of Class A common stock outstanding |
|
|
|
|
|
|
||
Basic |
|
|
|
|
|
|
||
Diluted |
|
|
|
|
|
|
||
Net income (loss) per share of Class A common stock |
|
|
|
|
|
|
||
Basic |
|
$ |
|
|
$ |
( |
) |
|
Diluted |
|
$ |
( |
) |
|
$ |
( |
) |
Weighted average number of shares of Class B common stock outstanding |
|
|
|
|
|
|
||
Basic |
|
|
|
|
|
|
||
Diluted |
|
|
|
|
|
|
||
Net income (loss) per share of Class B common stock |
|
|
|
|
|
|
||
Basic |
|
$ |
|
|
$ |
( |
) |
|
Diluted |
|
$ |
( |
) |
|
$ |
( |
) |
(1) The Company recognized gains on change in fair value of the Convertible Notes held by the CEO and CTO of $
(2) The Company recognized gains on change in fair value of Company Warrants held by the CEO and CTO of $
(4) The Company recognized a gain of $
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
2
ASTRA SPACE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(In thousands)
(Unaudited)
|
|
Three Months Ended |
|
|||||
|
|
2024 |
|
|
2023 |
|
||
Net income (loss) |
|
$ |
|
|
$ |
( |
) |
|
Other comprehensive income: |
|
|
|
|
|
|
||
Unrealized gain on available-for-sale marketable securities |
|
|
|
|
|
|
||
Total comprehensive income (loss) |
|
$ |
|
|
$ |
( |
) |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
3
ASTRA SPACE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
(In thousands, except share data)
(Unaudited)
Three Months Ended March 31, |
|
||||||||||||||||||||||||||||||||
|
Class A Common Stock |
|
|
Class B Common Stock |
|
|
Additional |
|
|
Accumulated Other Comprehensive |
|
|
Accumulated |
|
|
Total Stockholders' |
|
||||||||||||||||
|
Shares |
|
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Loss |
|
|
Deficit |
|
|
Deficit |
|
|||||||||
Balance as of December 31, 2023 |
|
|
|
- |
|
$ |
|
|
|
|
|
$ |
|
|
$ |
|
|
$ |
— |
|
|
$ |
( |
) |
|
$ |
( |
) |
|||||
Stock-based compensation |
|
— |
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
|||
Issuance of common stock under equity plans |
|
|
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
|||||
Net income |
|
— |
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|||
Balance as of March 31, 2024 |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
|
$ |
|
|
$ |
— |
|
|
$ |
( |
) |
|
$ |
( |
) |
Three Months Ended March 31, |
|
||||||||||||||||||||||||||||||
|
Class A Common Stock |
|
|
Class B Common Stock |
|
|
Additional |
|
|
Accumulated Other Comprehensive |
|
|
Accumulated |
|
|
Total Stockholders' |
|
||||||||||||||
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Loss |
|
|
Deficit |
|
|
Equity |
|
||||||||
Balance as of December 31, 2022 |
|
|
|
$ |
|
|
|
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
|
||||||
Stock-based compensation |
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
|||
Issuance of common stock under equity plans |
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
|
|||
Unrealized gain on available-for-sale marketable securities |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
— |
|
|
|
|
||
Net loss |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
( |
) |
Balance as of March 31, 2023 |
|
|
|
$ |
|
|
|
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4
ASTRA SPACE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
|
|
Three Months Ended |
|
|||||
|
|
2024 |
|
|
2023 |
|
||
Cash flows from operating activities: |
|
|
|
|
|
|
||
Net income (loss) |
|
$ |
|
|
$ |
( |
) |
|
Adjustments to reconcile net income (loss) to cash flows used in operating activities |
|
|
|
|
|
|
||
Stock-based compensation |
|
|
|
|
|
|
||
Depreciation |
|
|
|
|
|
|
||
Amortization of intangible assets |
|
|
|
|
|
|
||
Non-cash lease expense |
|
|
|
|
|
|
||
Gain on change in fair value of contingent consideration |
|
|
|
|
|
( |
) |
|
Gain on change in fair value of Convertible Notes(1) |
|
|
( |
) |
|
|
|
|
Gain on change in fair value of Warrant Liabilities(1) |
|
|
( |
) |
|
|
|
|
Amortization of marketable securities purchased at a discount |
|
|
|
|
|
( |
) |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
||
Trade accounts receivable |
|
|
( |
) |
|
|
( |
) |
Inventories |
|
|
( |
) |
|
|
( |
) |
Prepaid and other current assets |
|
|
|
|
|
( |
) |
|
Other non-current assets |
|
|
|
|
|
( |
) |
|
Accounts payable |
|
|
|
|
|
|
||
Lease liabilities |
|
|
( |
) |
|
|
( |
) |
Accrued expenses and other current liabilities |
|
|
( |
) |
|
|
|
|
Contract liabilities |
|
|
|
|
|
|
||
Other non-current liabilities |
|
|
|
|
|
|
||
Net cash used in operating activities |
|
$ |
( |
) |
|
$ |
( |
) |
Cash flows from investing activities: |
|
|
|
|
|
|
||
Proceeds from sales of marketable securities |
|
|
|
|
|
|
||
Purchases of property, plant and equipment |
|
|
( |
) |
|
|
( |
) |
Net cash (used in) provided by investing activities |
|
$ |
( |
) |
|
$ |
|
|
Cash flows from financing activities: |
|
|
|
|
|
|
||
Proceeds from issuance of convertible notes |
|
|
|
|
|
|
||
Proceeds from issuance of warrants |
|
|
|
|
|
|
||
Proceeds from issuance of common stock under equity award and purchase plans |
|
|
|
|
|
|
||
Net cash provided by financing activities |
|
$ |
|
|
$ |
|
||
Net increase (decrease) in cash and cash equivalents |
|
$ |
|
|
$ |
( |
) |
|
Cash and cash equivalents and restricted cash at beginning of period |
|
|
|
|
|
|
||
Cash and cash equivalents and restricted cash at end of period |
|
$ |
|
|
$ |
|
||
Non-cash investing and financing activities: |
|
|
|
|
|
|
||
Assets acquired included in accounts payable, accrued expenses and other current liabilities |
|
$ |
|
|
$ |
|
(1) Refer to the Condensed Consolidated Statements of Operations for descriptions of related party transactions.
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5
ASTRA SPACE, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 1 — Description of Business, Basis of Presentation and Significant Accounting Policies
Description of Business
Astra Space, Inc. (including its subsidiaries, "Astra" or the "Company") designs, tests, manufactures and operates the next generation of Launch Services and Space Products and services that it expects to enable a new generation of global communications, earth observations, precision weather monitoring, navigation, and surveillance capabilities. The Company's mission is to Improve Life on Earth from Space® through greater connectivity and more regular observations and to enable a wave of innovation in Low Earth Orbit ("LEO") by expanding its space platform offerings. Currently, the Company's business consists of
The Company’s Class A common stock is listed on the Nasdaq Capital Market under the symbol “ASTR”.
Basis of Presentation and Principles of Consolidation
Reclassification
Certain prior period amounts have been reclassified to conform to the current period presentation. The impact of these reclassifications was not material to the condensed financial statements for the periods presented.
Merger Agreement
On March 7, 2024, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Apogee Parent Inc. (“Parent”) and Apogee Merger Sub Inc. (“Merger Sub”) pursuant to which Merger Sub will merge with and into the Company, with the Company as the surviving corporation. The Merger Agreement was approved by stockholders holding the requisite voting power on March 7, 2024 and is expected to close during the second quarter of 2024. Once completed, the Company will no longer be a public company and is expected to delist from Nasdaq.
Reverse Stock Split
On September 12, 2023, the Company effectuated a
Unless otherwise noted, share numbers and per share amounts in this Quarterly Report on Form 10-Q reflect the Reverse Stock Split.
Impact of the Reverse Stock Split
The impacts of the Reverse Stock Split were applied retroactively for all periods presented in accordance with applicable guidance. Therefore, prior period amounts are different than those previously reported. Certain amounts within the following tables may not foot due to rounding.
6
The following table illustrates changes in equity, as previously reported prior to, and as adjusted subsequent to, the impact of the Reverse Stock Split retroactively adjusted for the periods presented:
|
|
|
|
March 31, 2023 |
|
|||||||||||||
|
|
|
|
|
|
|
|
As Previously Reported |
|
|
Impact of Reverse Stock Split |
|
|
As Adjusted |
|
|||
Class A common stock |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
||
Class B common stock |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
The following table illustrates changes in loss per share and weighted average shares outstanding, as previously reported prior to, and as adjusted subsequent to, the impact of the Reverse Stock Split retroactively adjusted for the periods presented:
|
|
|
|
Three Months Ended March 31, 2023 |
|
|||||||||||||
|
|
|
|
|
|
|
|
As Previously Reported |
|
|
Impact of Reverse Stock Split |
|
|
As Adjusted |
|
|||
Class A common stock: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Weighted average shares outstanding - basic and diluted |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
||
Loss per share - basic and diluted |
|
|
|
|
|
|
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
Class B common stock: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Weighted average shares outstanding - basic and diluted |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
||
Loss per share - basic and diluted |
|
|
|
|
|
|
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
The following outstanding stock options and restricted stock units exercisable or issuable into shares of Class A common stock were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive:
|
|
|
|
March 31, 2023 |
|
|||||||||||||
|
|
|
|
|
|
|
|
As Previously Reported |
|
|
Impact of Reverse Stock Split |
|
|
As Adjusted |
|
|||
Stock options |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
||
Restricted stock units |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
||
Warrants |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
||
Total antidilutive shares excluded from loss per share - diluted |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
Restricted stock awards were adjusted retroactively to give effect to the Reverse Stock Split for the three months ended March 31, 2023
|
|
As Previously Reported |
|
|
Impact of Reverse Stock Split |
|
|
As Adjusted |
|
|||||||||||||||
|
|
No. of |
|
|
Weighted- Average Exercise Price |
|
|
No. of |
|
|
Weighted- Average Exercise Price |
|
|
No. of |
|
|
Weighted- Average Exercise Price |
|
||||||
Outstanding - December 31, 2022 |
|
|
|
|
$ |
|
|
|
( |
) |
|
$ |
|
|
|
|
|
$ |
|
|||||
Granted |
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|||||
Vested |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
||||
Forfeited |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
||||
Outstanding - March 31, 2023 |
|
|
|
|
$ |
|
|
|
( |
) |
|
$ |
|
|
|
|
|
$ |
|
Stock options were adjusted retroactively to give effect to the Reverse Stock Split for the three months ended March 31, 2023:
|
|
As Previously Reported |
|
|
Impact of Reverse Stock Split |
|
|
As Adjusted |
|
|||||||||||||||
|
|
No. of |
|
|
Weighted- Average Exercise Price |
|
|
No. of |
|
|
Weighted- Average Exercise Price |
|
|
No. of |
|
|
Weighted- Average Exercise Price |
|
||||||
Outstanding - December 31, 2022 |
|
|
|
|
$ |
|
|
|
( |
) |
|
$ |
|
|
|
|
|
$ |
|
|||||
Granted |
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|||||
Exercised |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
||||
Forfeited |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
||||
Expired |
|
|
( |
) |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
||||
Outstanding - March 31, 2023 |
|
|
|
|
$ |
|
|
|
( |
) |
|
$ |
|
|
|
|
|
$ |
|
Liquidity
The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date
7
these unaudited condensed consolidated financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.
Pursuant to the requirements of ASC Topic 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date these unaudited condensed consolidated financial statements are issued. This evaluation does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented or are not within the control of the Company as of the date the unaudited condensed consolidated financial statements are issued. When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the unaudited condensed consolidated financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements are issued.
The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern over the next twelve months through May 2025. Since inception, the Company has incurred significant operating losses and has an accumulated deficit of approximately $
To proceed with the Company’s business plan and continue the Company's business operations, the Company will need to raise substantial additional funds through the issuance of additional debt, equity or both. Under the terms of the Merger Agreement, the Company is restricted from incurring new debt or issuing equity except through the offer and sale of the convertible notes due
There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or on terms that would be permissible under the restrictions imposed by the Merger Agreement.
As a result of these uncertainties, and notwithstanding management’s plans and efforts to date, there is substantial doubt about the Company’s ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements. If the Company is unable to raise substantial additional capital in the near term and as necessary to continue the Company's operations prior to the closing of the Merger, the Company’s operations and production plans may be further scaled back or curtailed or cease entirely, and the Company may be required to furlough employees to manage its short term cash needs. Further, the Company may be required to file a Chapter 7 Liquidation and in such case, may not realize any significant value from its assets in connection with a liquidation.
The Company has, however, prepared these unaudited condensed consolidated financial statements on a going concern basis, assuming that the Company's financial resources will be sufficient to meet its capital needs over the next twelve months. Accordingly, the Company's financial statements do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should it be unable to continue in operation for the next twelve months.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents and accounts receivable. The Company maintains cash and cash equivalent balances in bank accounts with multiple banking partners. All
8
cash accounts are located in the United States (“U.S.”) and insured by the FDIC up to $
The following customer's outstanding accounts receivable accounted for greater than 10% of the Company's trade accounts receivable as of the date reflected:
|
|
March 31, 2024 |
|
December 31, 2023 |
Customer 1 |
|
|
For the three months ended March 31, 2024 and 2023, one customer accounted for greater than 10% of the Company's total revenues:
|
|
Three Months Ended |
||
|
|
2024 |
|
2023 |
Customer 2 |
|
|
____________
Use of Estimates and Judgments
The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities in the unaudited condensed consolidated financial statements and accompanying notes. The Company bases these estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ significantly from those estimates. Significant items subject to such estimates and assumptions include the valuation of our Convertible Notes and Company Warrants and long-lived assets, inventory valuation and reserves, stock-based compensation, useful lives of intangible assets and property, plant and equipment, deferred tax assets, income tax uncertainties and other contingencies.
Significant Accounting Policies
There have been no changes to the Company’s significant accounting policies described in the Company’s 2023 Annual Report that have had a material impact on its unaudited condensed consolidated financial statements and related notes.
Recently Adopted Accounting Standards
There have been no new accounting standards applicable to the Company that have been adopted during the three months ended March 31, 2024.
Recently Issued Accounting Standards Not Yet Adopted
In December 2023, the Financial Accounting Standards Board (“FASB") issued Accounting Standards Update (“ASU") 2023-09 (ASC Topic 740), Improvements to Income Tax Disclosures ("ASU 2023-09"). This ASU requires disaggregated income tax disclosures on the rate reconciliation and income taxes paid. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 for publicly traded companies and December 15, 2025 for private companies. Early adoption is permitted for annual financial statements not yet issued or made available for issuance. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements and disclosures.
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"). ASU 2023-07 updates reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance. ASU 2023-07 is effective for public companies for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements and disclosures.
9
Note 2 — Revenues
The Company recognizes revenue at a point in time upon satisfaction of the performance obligations under its Launch Services and Space Products agreements. The following table presents revenue disaggregated by type for the periods presented:
|
|
Three Months Ended |
|
|||||
in thousands |
|
2024 |
|
|
2023 |
|
||
Launch services |
|
$ |
|
|
$ |
|
||
Space products |
|
|
|
|
|
|
||
Total revenues |
|
$ |
|
|
$ |
|
Contracts with governmental entities involving research and development milestone activities do not represent contracts with customers under ASC 606 and as such, amounts received are recorded in other income in the unaudited condensed consolidated statements of operations. The Company recorded
Contract balances
Contract assets and liabilities reflect timing differences between the receipt of consideration and the fulfillment of performance obligations under a contract with a customer. Contract assets reflect performance obligations satisfied and revenues recognized in advance of a customer billing. Contract liabilities reflect consideration received in advance of the satisfaction of a performance obligation under a contract with a customer. Contract assets become trade receivables once the Company's rights to consideration become unconditional. Such rights are considered unconditional if only the passage of time is required before payment of that consideration is due. Contract costs are those costs which are directly related to fulfillment of specified customer contracts. The Company had deferred contract costs of $
Remaining performance obligations
Revenue allocated to remaining performance obligations represents the transaction price allocated to the performance obligations that are unsatisfied, or partially unsatisfied. It includes unearned revenue and amounts that will be invoiced and recognized as revenue in future periods and does not include contracts where the customer is not committed. Customers are not considered committed when they are able to terminate their contractual obligations to the Company without payment of a substantial penalty under the contract. The Company had unsatisfied performance obligations based on contractual terms of $
Note 3 — Supplemental Financial Information
Inventories
in thousands |
|
March 31, |
|
|
December 31, |
|
||
Raw materials |
|
$ |
|
|
$ |
|
||
Work in progress |
|
|
|
|
|
|
||
Inventories |
|
$ |
|
|
$ |
|
There were
Prepaid and Other Current Assets
in thousands |
|
March 31, |
|
|
December 31, |
|
||
Deposits |
|
$ |
|
|
$ |
|
||
Prepaid license and other prepaid expenses |
|
|
|
|
|
|
||
Deferred contract costs |
|
|
|
|
|
|
||
Other current assets |
|
|
|
|
|
|
||
Prepaid and other current assets |
|
$ |
|
|
$ |
|
10
Property, Plant and Equipment, net
Presented in the table below are the major classes of property, plant and equipment:
in thousands |
|
March 31, |
|
|
December 31, |
|
||
Construction in progress |
|
$ |
|
|
$ |
|
||
Computer and software |
|
|
|
|
|
|
||
Leasehold improvements |
|
|
|
|
|
|
||
Research equipment |
|
|
|
|
|
|
||
Production equipment |
|
|
|
|
|
|
||
Furniture and fixtures |
|
|
|
|
|
|
||
Total property, plant and equipment |
|
|
|
|
|
|
||
Less: accumulated depreciation |
|
|
( |
) |
|
|
( |
) |
Property, plant and equipment, net |
|
$ |
|
|
$ |
|
Depreciation expense amounted to $
Accrued Expenses and Other Current Liabilities
in thousands |
|
March 31, |
|
|
December 31, |
|
||
Employee compensation and benefits |
|
$ |
|
|
$ |
|
||
Construction in progress related accruals |
|
|
|
|
|
|
||
Professional services |
|
|
|
|
|
|
||
Accrued expenses |
|
|
|
|
|
|
||
Accrued inventory purchases |
|
|
|
|
|
|
||
Other miscellaneous |
|
|
|
|
|
|
||
Accrued expenses and other current liabilities |
|
$ |
|
|
$ |
|
Note 4 — Intangible Assets
in thousands |
|
Carrying Amount |
|
|
Accumulated Amortization |
|
|
Net Book Value |
|
|||
March 31, 2024 |
|
|
|
|
|
|
|
|
|
|||
Definite-lived intangible assets |
|
|
|
|
|
|
|
|
|
|||
Developed technology |
|
$ |
|
|
$ |
( |
) |
|
$ |
|
||
Customer contracts and related relationship |
|
|
|
|
|
( |
) |
|
|
|
||
Trade names |
|
|
|
|
|
( |
) |
|
|
|
||
Intangible assets subject to amortization |
|
|
|
|
|
( |
) |
|
|
|
||
Indefinite-lived intangible assets |
|
|
|
|
|
|
|
|
|
|||
Trademarks |
|
|
|
|
|
|
|
|
|
|||
Total |
|
$ |
|
|
$ |
( |
) |
|
$ |
|
There were
in thousands |
|
Carrying Amount |
|
|
Accumulated Amortization |
|
|
Net Book Value |
|
|||
December 31, 2023 |
|
|
|
|
|
|
|
|
|
|||
Definite-lived intangible assets |
|
|
|
|
|
|
|
|
|
|||
Developed technology |
|
$ |
|
|
$ |
( |
) |
|
$ |
|
||
Customer contracts and related relationship |
|
|
|
|
|
( |
) |
|
|
|
||
Trade names |
|
|
|
|
|
( |
) |
|
|
|
||
Intangible assets subject to amortization |
|
|
|
|
|
( |
) |
|
|
|
||
Indefinite-lived intangible assets |
|
|
|
|
|
|
|
|
|
|||
Trademarks |
|
|
|
|
|
|
|
|
|
|||
Total |
|
$ |
|
|
$ |
( |
) |
|
$ |
|
11
Based on the amount of intangible assets as of March 31, 2024, the expected amortization expense for each of the next five years and thereafter is as follows:
in thousands |
|
Expected Amortization Expense(1) |
|
|
2024 (remainder) |
|
$ |
|
|
2025 |
|
|
|
|
2026 |
|
|
|
|
2027 |
|
|
|
|
Total Intangible assets subject to amortization |
|
$ |
|
(1)
Note 5 — Fair Value Measurements
The Company measures its financial assets and liabilities at fair value each reporting period using a fair value hierarchy that prioritizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. A financial instrument’s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs may be used to measure fair value, as follows:
Level 1 Observable inputs, such as quoted prices in active markets for identical assets or liabilities;
Level 2 Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and
Level 3 Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
The carrying amounts of the Company's cash equivalents, accounts receivable, prepaid expenses, other current assets, accounts payable, accrued liabilities and certain other current liabilities approximate fair value because of their short-term maturities.
As of March 31, 2024 and December 31, 2023, the Company had a total of $
The following table presents information about the Company’s liabilities at March 31, 2024, that were measured at fair value on a recurring basis:
in thousands |
|
March 31, 2024 |
|
|||||||||||||
Description |
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
||||
Liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Warrants to purchase common stock |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Convertible Notes |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total financial liabilities |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
in thousands |
|
December 31, 2023 |
|
|||||||||||||
Description |
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
||||
Liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Warrants to purchase common stock |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Convertible Notes |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total financial liabilities |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
The following table presents a summary of the changes in fair value of the Company's Level 3 financial instruments:
12
in thousands |
|
Warrants |
|
|
Fair value as of December 31, 2023 |
|
$ |
|
|
Issuance of warrants at fair value |
|
|
|
|
Gain on change in fair value of warrants |
|
|
( |
) |
Fair value as of March 31, 2024 |
|
$ |
|
|
|
|
|
|
|
in thousands |
|
Convertible Notes |
|
|
Fair value as of December 31, 2023 |
|
$ |
|
|
Issuance of convertible notes at fair value |
|
|
|
|
Gain on change in fair value of convertible notes |
|
|
( |
) |
Fair value as of March 31, 2024 |
|
$ |
|
The $
Note 6 — Convertible Notes and Company Warrants
The following summarizes the Company's Convertible Notes and Company Warrants by investor as of March 31, 2024:
|
|
Convertible Notes |
|
|
Company Warrants(1) |
|
||||||||||||||||||
Investor |
|
Principal |
|
|
Accrued but Uncapitalized Interest |
|
|
Combined Principal and Accrued but Uncapitalized Interest |
|
|
Fair Value |
|
|
Number of Warrants Outstanding |
|
|
Fair Value |
|
||||||
JMCM Holdings LLC |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
|
|
|
$ |
|
||||||
SherpaVentures Fund II, LP(2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
MH Orbit, LLC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
RBH Ventures Astra SPV, LLC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Astera Institute |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
ERAS Capital, LLC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Ulrich Gall |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Founders: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Chris C. Kemp, Trustee of the Chris Kemp Living Trust dated February 10, 2021(2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Adam London(2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Total Convertible Notes and Warrants |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
|
|
|
$ |
|
(1) Includes the warrants issued on August 4, 2023 (the “Original Warrants”), which are exercisable to purchase
(2) Investor is a related party. SherpaVentures Fund II, LP (“ACME II) is an affiliate of Scott Stanford, a director of the Company. Chris C. Kemp, trustee of the Chris Kemp Living Trust dated February 10, 2021 (the “Kemp Trust”), is the Company Chairman and Chief Executive Officer (“CEO”). Adam London is the Chief Technology Officer (“CTO”) and a director of the Company.
13
The following summarizes the Company's Convertible Notes and Company Warrants by investor as of December 31, 2023:
|
|
Convertible Notes |
|
|
Company Warrants(1) |
|
||||||||||||||||||
Investor |
|
Principal |
|
|
Accrued but Uncapitalized Interest |
|
|
Combined Principal and Accrued but Uncapitalized Interest |
|
|
Fair Value |
|
|
Number of Warrants Outstanding |
|
|
Fair Value |
|
||||||
JMCM Holdings LLC |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
|
|
|
$ |
|
||||||
SherpaVentures Funds II, LP(2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Founders: |
|
|
|
|
|
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|||||
Chris Kemp(2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Adam London(2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Total Convertible Notes and Warrants |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
|
|
|
$ |
|
(1) Includes the warrants issued on August 4, 2023, which are exercisable to purchase
(2) Investor is a related party. SherpaVentures Fund II, LP is an affiliate of Scott Stanford, a director of the Company. Chris C. Kemp is the Company Chairman and CEO. Adam London is the CTO and a director of the Company.
Subsequent Financings
During the first quarter of 2024, the Company received additional investments of $
|
|
|
|
|
|
|
|
|
|
|
Allocation of Proceeds to Fair Value |
|
|
|
|
|||||||||||
Investor |
|
Date |
|
Principal |
|
|
Number of Warrants Issued |
|
|
Total Proceeds Received |
|
|
Convertible Notes |
|
|
Warrants |
|
|
Issuance Costs |
|
||||||
MH Orbit LLC |
|
|
$ |
|
|
|
|
|
$ |
|
|
|
|
|
$ |
|
|
$ |
|
|||||||
RBH Ventures Astra SPV LLC (1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Astera Institute |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
ERAS Capital, LLC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Urich Gall |
|
|
|
|
|
|
- |
|
|
|
|
|
|
|
|
|
- |
|
|
|
|
|||||
Founders: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Chris C. Kemp, Trustee of the Chris Kemp Living Trust dated February 10, 2021 (2) |
|
|
|
|
|
|
- |
|
|
|
|
|
|
|
|
|
- |
|
|
|
|
|||||
Adam London (2) |
|
|
|
|
|
|
- |
|
|
|
|
|
|
|
|
|
- |
|
|
|
|
|||||
Total Convertible Notes and Warrants |
|
|
|
$ |
|
|
|
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
(1) Includes an additional investment made by RBH Ventures on March 15, 2024 of $
(2) The CEO and CTO made additional investments in Convertible Notes of $
See Note 15 — Subsequent Events for information on additional sales of Convertible Notes and Company Warrants occurring after March 31, 2024.
Material Amendments to Subsequent Financing Agreement and Convertible Notes
On November 21, 2023, the Company entered into an Omnibus Amendment No. 3 Agreement, dated as of November 21, 2023, which agreement, subject to amendments occurring after such date, sets forth the terms and conditions upon which the Company may offer for sale and issue Convertible Notes and Company Warrants (the “Subsequent Financing Agreement”).
During the three months ended March 31, 2024, the Company and the holders of the Convertible Notes and Company Warrants amended or modified the Subsequent Financing Agreement and the Convertible Notes on January 19, 2024 (the “January 19 Amendment”), January 31, 2024 (the “January 31 Amendment”) and February 26, 2024 (the “February Amendment”).
The January 19 Amendment extended the date by which a Subsequent Closing (as defined the Subsequent Financing Agreement) may occur without the consent of a majority-in-interest of the Convertible Notes from January 20, 2024, to February 19, 2024, which date was further extended by the February Amendment to April 30, 2024.
14
The January 31 Amendment extended the first amortization payment under the Convertible Notes, which was originally due on February 1, 2024, to May 1, 2024.
The February Amendment also increased the maximum amount of the Aggregate Stated Principal Amount (as defined in the Subsequent Financing Agreement) of the Convertible Notes from $
See Note 15 – Subsequent Events for information about additional amendments to the Subsequent Financing Agreement and Convertible Notes occurring after March 31, 2024.
Fair Value of Company Warrants and Convertible Notes
Company Warrants
As of March 31, 2024, the Company had
The Company determined the fair value of the Company Warrants issued during the three months ended March 31, 2024 and of all Company Warrants outstanding as of March 31, 2024 based on an option pricing model ("OPM") considering the warrant exchange agreement between the Parent and holders of Company Warrants and the expected capital structure of the Parent following consummation of the Merger
The following is a summary of the assumptions used to determine the OPM fair value of the Company Warrants at each date of issuance and for all Company Warrants outstanding as of March 31, 2024:
|
|
|
|
January 19, |
|
|
March 6, |
|
|
March 31, |
|
|||
Expected terms (years) |
|
|
|
|
|
|
|
|
||||||
Expected volatility |
|
|
|
|
|
|
|
|
||||||
Risk-free interest rate |
|
|
|
|
|
|
|
|
||||||
Expected dividend rate |
|
|
|
|
|
|
|
|
||||||
Value per share |
|
|
|
$ |
|
|
$ |
|
|
$ |
|
|||
Exercise price |
|
|
|
$ |
|
|
$ |
|
|
$ |
|
|||
Implied Negotiation Discount |
|
|
|
|
|
|
|
|
(1) The Subsequent Financings that occurred on March 7, 2024, March 8, 2024 and March 15, 2024 applied the same fair value model and assumptions as those used for Subsequent Financing that occurred on March 6, 2024.
(2) Subsequent Financings that occurred on February 26, 2024 and March 8, 2024 did not include the purchase of Company Warrants.
The expected term is based on expectations with regard to an exit strategy such as an IPO or liquidation event of the Parent. The risk free rate was based on the rate of treasury securities with the same term as the option. The expected volatility was based on guideline company indications.
As of December 31, 2023, the Company had
|
|
|
|
December 31, |
|
|
Expected terms (years) |
|
|
|
|
||
Expected volatility |
|
|
|
|
||
Risk-free interest rate |
|
|
|
|
||
Expected dividend rate |
|
|
|
|
||
Value per share |
|
|
|
$ |
|
|
Exercise price |
|
|
|
$ |
|
15
Convertible Notes
During the three months ended March 31, 2024, the Company issued $
As of December 31, 2023, the Company had $
|
|
December 31, |
|
|
Risk-free interest rate |
|
|
||
Risk adjusted interest rate (for discount payment) |
|
|
||
Value per share |
|
$ |
|
|
Volatility |
|
|
Note 7 — Commitments and Contingencies
Legal Proceedings
The Company is party to ordinary and routine litigation incidental to its business. On a case-by-case basis, the Company engages inside and outside counsel to assess the probability of potential liability resulting from such litigation. After making such assessments, the Company makes an accrual for the estimated loss only when the loss is probable, and an amount can be reasonably estimated. The Company and or its current or former directors and officers are currently parties to the following litigation matters:
On April 27, 2022, a stockholder derivative suit was filed in the United States District Court for the Eastern District of New York styled Gonzalez v. Kemp, et al., Case No. 22-cv-02401 (E.D.N.Y.) (the “Gonzalez Action”). On January 25, 2023, the plaintiff filed an amended complaint. The amended complaint asserts claims against certain of the Company’s current and former officers and directors for alleged breaches of their fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, alleged violations of Section 14(a) of the Securities Exchange Act of 1934 (the “Exchange Act”), and for contribution under Section 10(b) and 21D of the Exchange Act based upon the conduct alleged in the Securities Action described above. The plaintiff in the Gonzalez Action seeks monetary damages in favor of the Company in an unstated amount, reforms to the Company’s corporate governance and internal procedures, restitution including disgorgement of any compensation, profits or other benefits received, and reimbursement of the plaintiff's reasonable fees and costs, including attorney’s fees. On February 17, 2023, the Gonzalez Action was transferred to the United States District Court for the Northern District of California under Case No. 3:23-cv-00713. Defendants filed a motion to dismiss the amended complaint on April 18, 2023. On June 12, 2023, the Court in the Gonzalez Action granted the Company’s motion to stay the case until a final judgment has been issued in the resolution of In re Astra Space f/k/a Holicity Inc. Securities Litigation (Case No. 3:22- cv-08875) in the Northern District of California (the “Securities Action. Once the Securities Action was dismissed, the Gonzalez Action again proceeded. Plaintiffs have filed an opposition to the Defendants motion to dismiss. Due to the announcement of the potential merger transaction (and the likely alternative of bankruptcy if the merger transaction does not close), the Court has again stayed the Gonzalez Action until at least July 9, 2024. The Company believes that the case is without merit and intends to defend it vigorously. Due to the early stage of the case, neither the likelihood that a loss, if any, will be realized, nor an estimate of the possible loss or range of loss, if any, can be determined.
Based on a Court of Chancery Rule 5.1 notice, on or about
16
the case, neither the likelihood that a loss, if any, will be realized, nor an estimate of the possible loss or range of loss, if any, can be determined.
The Company has tendered defense of each of the foregoing claims under its Directors’ and Officers’ policy. The retention under this policy is $
Indemnification Obligations to former Company Board Members
On May 20, 2022, a putative class action was filed in the Court of Chancery of the State of Delaware styled Newbold v. McCaw et. al., Case No. 2022-0439 (the “Newbold Action”). The complaint alleges that Pendrell Corporation, X-icity Holdings Corporation f/k/a Pendrell Holicity Holdings and certain former officers, directors or controlling stockholders of Holicity, Inc. n/k/a Astra Space, Inc., breached their fiduciary duties to the Company in closing on the Business Combination. The complaint seeks unspecified damages on behalf of a purported class of stockholders of the Company’s securities during a specified time period.
Neither the Company nor any of its board members are parties in this action. Mr. McCaw, who served as a former member of the Company’s board, is a defendant in this action, but the allegations relate to periods prior to the Business Combination. Astra is obligated to indemnify certain of the defendants in the Newbold Action. The Company has tendered defense of this action under its Directors’ and Officers' Policy. The Company also tendered defense of this claim under the tail policy it was required to purchase in connection with the Business Combination. The retention under the tail policy is $
Section 220 Demands
Following the announcement of the Merger Agreement, the Company has received demands to inspect the Company’s books and records pursuant to 8 Del. C. § 220 (“Section 220”). Specifically, on April 5, 2024, purported stockholder Jonathan Horner delivered a Section 220 demand to the Company, which demand was supplemented on April 11, 2024. On April 17, 2024, another purported stockholder, Michael Krene, represented by the same law firm, delivered a second Section 220 demand to the Company. On April 22, 2024, a third purported stockholder, Jerry Hamelton, delivered a Section 220 demand to the Company (collectively, the “Section 220 Demands”).
Although the specifics of each Section 220 Demand varies, they generally intend to investigate the events leading to execution of the Merger Agreement, to investigate the independence and disinterestedness of certain members of the Company’s board of directors and officers in connection with the Merger Agreement and the Merger, and to determine whether such directors and officers properly discharged their fiduciary duties, investigate the Company’s disclosures regarding the Merger Agreement and the Merger. The Section 220 Demands seek to inspect the Company’s books and records to determine whether wrongdoing, mismanagement, and/or material non-disclosure has taken place such that it would be appropriate to file an action against the Board, the officers, the Company, or any other relevant person or entity, to value each stockholder’s shares, and to consider any other courses of action that the investigation might warrant pursuing.
The Company is evaluating each of the Section 220 Demands and intends to defend vigorously any allegation of wrongdoing, mismanagement and/or non-disclosure. Due to the early stage of these investigations, neither the likelihood that a loss, if any, will be realized, nor an estimate of the possible loss or range of loss, if any, can be determined.
Commercial Contracts
The Company has received notices of termination from two customers. The total contract value of these two agreements was $
Purchase Commitments
In order to reduce manufacturing lead times and to have access to an adequate supply of components, the Company enters into agreements with certain suppliers to procure component inventory based on the Company's production needs. A significant portion of the Company's purchase commitments arising from these agreements consist of firm and non-cancelable commitments. We have one such supplier contract which is active at this time. While we are currently in a dispute with this supplier over the performance of this contract, there remains $
Note 8 — Stock-based Compensation
Stock-based incentive awards are provided to employees under the terms of Astra's 2021 Omnibus Incentive Plan (the “2021 Plan”) and the 2023 Bonus Incentive Plan and 2021 Employee Stock Purchase Plan (the “2021 ESPP”). Unless otherwise noted,
17
There was a $
As of March 31, 2024, the Company has not established a 2024 Bonus Incentive Plan and as such,
The following table summarizes stock-based compensation expense for the three months ended March 31, 2024 and 2023:
|
|
Three Months Ended |
|
|||||
in thousands |
|
2024 |
|
|
2023 |
|
||
Cost of revenues |
|
$ |
|
|
$ |
|
||
Research and development |
|
|
|
|
|
|
||
Sales and marketing |
|
|
|
|
|
|
||
General and administrative |
|
|
|
|
|
|
||
Stock-based compensation expense |
|
$ |
|
|
$ |
|
As of March 31, 2024, the Company had $
Stock Options Awards
The following is a summary of stock option activity for the three months ended March 31, 2024:
|
|
No. of |
|
|
Weighted- Average Exercise Price |
|
|
Weighted- Average |
|
|
Aggregate Intrinsic |
|
||||
Outstanding – December 31, 2023 |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
||||
Granted |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|||
Exercised |
|
|
( |
) |
|
|
|
|
|
— |
|
|
|
— |
|
|
Forfeited/Cancelled |
|
|
( |
) |
|
|
|
|
|
— |
|
|
|
— |
|
|
Expired |
|
|
( |
) |
|
|
|
|
|
— |
|
|
|
— |
|
|
Outstanding – March 31, 2024 |
|
|
|
|
$ |
|
|
|
|
|
$ |
— |
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Unvested – March 31, 2024 |
|
|
|
|
|
|
|
|
|
|
|
— |
|
|||
Exercisable – March 31, 2024 |
|
|
|
|
$ |
|
|
|
|
|
$ |
— |
|
18
The Company uses the Black-Scholes option pricing-model to calculate the grant date fair value of time-based and performance-based options. The following table summarizes the assumptions used in estimating the fair value of options granted in the three months ended March 31, 2024 and 2023:
|
|
Three Months Ended March 31, |
|
|||||
|
|
2024 |
|
|
2023 |
|
||
Expected terms (years) |
|
|
|
|
|
|
||
Expected volatility |
|
|
|
|
||||
Risk-free interest rate |
|
|
|
|
||||
Expected dividend rate |
|
|
|
|
||||
Grant-date fair value |
|
$ |
|
|
$ |
|
____________
Restricted Stock Units ("RSU") Awards
The following is a summary of restricted stock units for the three months ended March 31, 2024:
|
|
Number of RSUs Outstanding |
|
|
Weighted- Average Grant Date Fair Value Per Share |
|
||
Outstanding – December 31, 2023 |
|
|
|
|
$ |
|
||
Granted |
|
|
|
|
|
|
||
Vested |
|
|
( |
) |
|
|
|
|
Forfeited |
|
|
( |
) |
|
|
|
|
Outstanding – March 31, 2024 |
|
|
|
|
$ |
|
Total fair value as of the respective vesting dates of restricted stock units vested for the three months ended March 31, 2024 was approximately $
2021 ESPP
The 2021 ESPP, which is maintained by the Company, allows employees to purchase the Company’s common stock at a discount of up to
Note 9 — Income Taxes
The Company computes its provision for income taxes by applying the estimated annual effective tax rate to year-to-date income from recurring operations and adjusts the provision for discrete tax items recorded in the period.
There has historically been no federal or state provision for income taxes because the Company has incurred operating losses and maintains a full valuation allowance against its net deferred tax assets. For the three months ended March 31, 2024 and 2023, the Company recognized
Utilization of net operating loss carryforwards, tax credits and other attributes may be subject to future annual limitations due to the ownership change limitations provided by Section 382 of the Internal Revenue Code and similar state provisions.
The Company files income tax returns in the U.S. federal jurisdiction and various states. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. All tax returns will remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss or credits.
19
Note 10 — Income (Loss) per Share
The Company computes earnings (loss) per share of Common Stock using the two-class method required for participating securities. Basic earnings (loss) per common share is determined based on the weighted-average number of common shares outstanding during each period. For periods with net income, the Company gives effect to all dilutive potential common shares outstanding during a period. The Company uses the control number concept to determine whether a potential common stock instrument is dilutive, and considers each issuance separately for its potential dilution in order of the most dilutive issuance to the least. For periods with net loss, diluted earnings per share will consider whether the inclusion of all potential Common Stock outstanding would be anti-dilutive. The dilutive effect of outstanding options and warrants is calculated using the treasury stock method. The dilutive effect of shares underlying the Company's Convertible Notes is calculated using the if-converted method in periods during which Convertible Notes are available for conversion.
The following tables set forth the computation of basic and diluted income (loss) for the three months ended March 31, 2024 and 2023:
|
|
Three Months Ended March 31, |
|
|||||||||||||
|
|
2024 |
|
|
2023 |
|
||||||||||
(in thousands, except share and per share amounts) |
|
Class A |
|
|
Class B |
|
|
Class A |
|
|
Class B |
|
||||
Numerator |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net income (loss) attributed to common stockholders - Basic |
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
||
Gain on change in fair value of Warrants |
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
|
||
Gain on change in fair value of Convertible Notes |
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
|
||
Net loss - Diluted |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Denominator |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Weighted-average common shares outstanding - Basic |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Effect of dilutive securities: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Common shares issuable for Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Common shares issuable for Convertible Notes |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Weighted-average common shares outstanding - Diluted |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net income (loss) per share - Basic |
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
( |
) |
||
Net loss per share - Diluted |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
There were
|
|
March 31, |
|
|||||
|
|
2024 |
|
|
2023 |
|
||
Stock options |
|
|
|
|
|
|
||
RSUs |
|
|
|
|
|
|
||
Convertible Notes |
|
|
|
|
|
|
||
Warrants |
|
|
|
|
|
|
||
Total |
|
|
|
|
|
|
There were
20
Note 11 — Segment Information
The Company reports segment information based on a “management” approach to reflect the operating segments for which the Company’s Chief Executive Officer, as the Chief Operating Decision Maker (“CODM”), makes decisions and assesses performance. The Company has
Launch Services segment provides rapid, global, and affordable launch services to satellite operators and governments.
Space Products consist of designing and providing space products based on the customers' needs for a successful satellite launch.
All intercompany revenues and expenses are eliminated in the consolidated financial statements.
The following table shows revenue by reporting segment for the three months ended March 31, 2024 and 2023:
|
|
Three Months Ended |
|
|||||
in thousands |
|
2024 |
|
|
2023 |
|
||
Revenues: |
|
|
|
|
|
|
||
Launch services |
|
$ |
|
|
$ |
|
||
Space products |
|
|
|
|
|
|
||
Total revenues: |
|
$ |
|
|
$ |
|
||
|
|
|
|
|
|
|
||
Cost of revenues: |
|
|
|
|
|
|
||
Launch services |
|
$ |
|
|
$ |
|
||
Space products |
|
|
|
|
|
|
||
Total cost of revenues: |
|
$ |
|
|
$ |
|
||
|
|
|
|
|
|
|
||
Gross profit: |
|
|
|
|
|
|
||
Launch services |
|
$ |
|
|
$ |
|
||
Space products |
|
|
|
|
|
|
||
Total gross profit: |
|
$ |
|
|
$ |
|
The Company evaluates the performance of its reporting segments based on segment gross profit. Segment gross profit is segment revenue less segment cost of revenue. Unallocated expenses include operating expenses related to research and development, selling and marketing and general and administrative expenses as they are not considered when management evaluates segment performance.
The following table reconciles segment gross profit to loss before income taxes for the three months ended March 31, 2024 and 2023:
|
|
Three Months Ended |
|
|||||
in thousands |
|
2024 |
|
|
2023 |
|
||
Gross profit |
|
$ |
|
|
$ |
|
||
Research and development |
|
|
|
|
|
|
||
Selling and marketing |
|
|
|
|
|
|
||
General and administrative |
|
|
|
|
|
|
||
Gain on change in fair value of contingent consideration |
|
|
|
|
|
( |
) |
|
Interest income |
|
|
( |
) |
|
|
( |
) |
Other income, net |
|
|
( |
) |
|
|
( |
) |
Gain on change in fair value of Convertible Notes |
|
|
( |
) |
|
|
|
|
Gain on change in fair value of warrants |
|
|
( |
) |
|
|
|
|
Income (loss) before taxes |
|
$ |
|
|
$ |
( |
) |
The Company does not evaluate performance or allocate resources based on reporting segment’s total assets or operating expenses, and therefore such information is not presented.
All of the Company’s long-lived assets are located in the United States. The Company is subject to International Traffic in Arms Regulations (“ITAR”) and generates all of its revenue in the United States.
21
Note 12 — Related Party Transactions
In addition to Convertible Notes and Company Warrants held by the Kemp Trust, Dr. London and affiliates of Mr. Stanford (the “Related Party Note and Warrant Holders”) at December 31, 2023, the following additional related party transactions occurred with respect to the Related Party Note and Warrant Holders during the three months ended March 31, 2024:
Note 13 — AST License Agreement
On March 6, 2024, a subsidiary of the Company, entered into a Royalty Bearing Manufacturing License (the “Manufacturing License”) with Astra Space Technologies Holding, Inc ("AST"). The Company and AST are parties to a Supply and Manufacturing Agreement, dated April 28, 2022 (the “Supply Agreement”), pursuant to which the Company manufactures certain spacecraft engines, flight sets, power processing units and feed systems (the “AST Products”) for AST. The Manufacturing License, among other things, provides AST a license to manufacture the AST Products for its internal use as a means to increase the quantity of AST Products available in the future and to provide an alternative source of supply for a critical component. The Manufacturing License is a limited, non-exclusive, non-transferable, irrevocable, non-sublicensable, fully paid license to make and have made a specified number of AST Products. In consideration of the Manufacturing License, on March 6, 2024, AST paid the Company $
Note 14 — Merger Agreement
As disclosed in Note 1 — Description of Business, Basis of Presentation and Significant Accounting Policies, on
At the Effective Time, by virtue of the occurrence of the Merger, the following will occur:
22
Following the execution of the Merger Agreement, and pursuant to the terms of the Merger Agreement, the Company (i) deposited into a segregated bank account of Astra Space Operations LLC (the “Segregated Account”) an amount in cash equal to $
All outstanding Convertible Notes will, immediately after the Merger becomes effective, be converted into shares of Series A preferred stock, par value $
Pursuant to the Merger Agreement, at the Effective Time, each outstanding option to purchase Class A Shares (each, a “Company Option”) other than a Company Option with an exercise price equal to or greater than the Merger Consideration (an “Underwater Option”), that is outstanding immediately prior to the Effective Time, whether vested or unvested, will be assumed by Parent and converted into an option (the “Converted Options”) to purchase shares of class A common stock, par value $
In addition, at the Effective Time, each outstanding restricted stock unit with respect to Class A Shares (a “Company RSU Award” and collectively with the Company Options, the “Company Equity Awards”) held by any director of the Company who is not an employee of the Company (a “Director RSU Award”) will be accelerated in full. At the Effective Time, each Company RSU Award that has vested in accordance with its terms, or so accelerated in the case of Director RSU Awards (except for Rollover Shares that are issued upon acceleration of Director RSU Awards) will be canceled and will only entitle the holder of such Company RSU Award to receive (without interest) an amount in cash equal to (i) the number of Class A Shares subject to such Company RSU Award immediately prior to the Effective Time multiplied by (ii) the Merger Consideration. At the Effective Time, each Company RSU Award that has not vested in accordance with its terms or so accelerated will be canceled for no consideration.
The execution and delivery of the Merger Agreement, subject to the requisite stockholder approval was recommended by the Special Committee to the Board on March 5, 2024. On March 5, 2024, the Board, with Mr. Kemp, Dr. London and Mr. Stanford abstaining, approved the execution and delivery of the Merger Agreement and recommended the adoption of the Merger Agreement and the Merger to the stockholders of the Company. On March 7, 2024, following the execution of the Merger Agreement, Mr. Kemp and Dr. London, who on such date beneficially owned Common Shares representing approximately
Note 15 — Subsequent Events
Additional Purchases of Convertible Notes and Company Warrants under Subsequent Financing Agreement
On April 22, 2024, RBH Ventures purchased $
23
were $
On May 13, 2024, Astera Institute purchased $
Amendments to Subsequent Financing Agreement and Convertible Notes
The Company and the holders of the Convertible Notes and Company Warrants amended or modified the Subsequent Financing Agreement and the Convertible Notes on April 10, 2024 (the “April 10 Amendment”) and on April 30, 2024 (the “April 30 Amendment”).
The April 10 Amendment extended the date by which a Subsequent Closing (as defined the Subsequent Financing Agreement) may occur without the consent of a majority-in-interest of the Convertible Notes from April 30, 2024, to June 30, 2024, It also amended the Subsequent Financing Agreement by extending all obligations of the Company that are due on May 1, 2024 (other than the amortization payment due under the Convertible Notes) to August 1, 2024, as well as extending the date by which the Company must obtain the Stockholder Approval required under Section 4(cc) of the Subsequent Financing Agreement to the later to occur of (i) August 1, 2024, or (ii) the first annual meeting of stockholders to take place after November 21, 2023.
Pursuant to the April 30 Amendment, the Company and the holders of Convertible Notes agreed that no Amortization Payment (as defined in the Convertible Note) shall be due on May 1, 2024 and the first Amortization Payment shall instead be due and payable on June 1, 2024, in an amount equal to
24
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis of the financial condition and results of operations of Astra Space, Inc. should be read together with our audited consolidated financial statements as of and for the years ended December 31, 2023 and 2022 and unaudited condensed consolidated financial statements as of and for the three months ended March 31, 2024 and 2023, together with related notes thereto. This discussion may contain forward-looking statements based upon current expectations that involve risks and uncertainties. This quarterly report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms “anticipate,” “expect,” “estimate,” “seek,” “plan,” “project,” “aim,” “believe,” “could,” “should,” “intend,” “will,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements may include projections of financial information; statements about historical results that may suggest trends for our business; statements of the plans, strategies, and objectives of management for future operations; and statements of expectation or belief regarding future events (including any acquisitions we may make), technology developments, our products, product sales, expenses, liquidity, cash flow and growth rates. Such statements are based on management’s current expectations, estimates, forecasts and projections of our performance, our industry’s performance and macroeconomic conditions, judgment, beliefs, views on current trends and market conditions. Such forward-looking statements inherently involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. We derive most of our forward-looking statements from our operating budgets and forecasts, which are based upon many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. Accordingly, we caution readers not to place undue reliance on these statements. Forward-looking statements in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference may include, for example, statements about:
These forward-looking statements are based on information available as of the date of this quarterly report on Form 10-Q and on management’s current expectations, forecasts and assumptions. These forward-looking statements involve a number of judgments, risks and uncertainties. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements such as those contained in documents we have filed with the SEC. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update or revise
25
forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. For a discussion of the risks involved in our business, see the section entitled, “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2023, filed with the SEC on April 18, 2024 ("2023 Annual Report"). Should one or more of these risks or uncertainties materialize, or should any of the underlying assumptions prove incorrect, actual results may vary in material respects from those expressed or implied by these forward-looking statements. Investors should not place undue reliance on these forward-looking statements.
Certain amounts may not foot due to rounding. Unless the context otherwise requires, all references in this section to “the Company” “Astra,” “us,” “our” or “we” refer to Astra Space, Inc.
A discussion regarding our financial condition and results of operations for the three months ended March 31, 2024 and 2023 is presented below. All prior period share and per share amounts (unless otherwise noted) included in our discussion of our financial condition and results of operations have been restated on a 1 to 15 reverse stock split basis, which became effective September 13, 2023. For additional information related to our Reverse Stock Split, see Note 1 — Description of Business, Basis of Presentation and Significant Accounting Policies under the caption, Reverse Stock Split in this Quarterly Report.
Overview
Astra’s mission is to launch a new generation of Launch Services and Space Products to Improve Life on Earth from Space®. These products and services are enabled by new constellations of small satellites in Low Earth Orbit (“LEO”), which have rapidly become smaller, cheaper, and many times more numerous than legacy satellites. Launch vehicles, however, have not evolved in the same way—most rockets remain focused on serving legacy satellites and human spaceflight missions and we aim to provide the world’s first mass produced orbital launch system. Our primary focus remains the growth and development of our Launch Services and Space Products offerings to support our overall mission to Improve Life on Earth from Space®. We manage our business and report our financial results in two segments: Launch Services and Space Products.
Recent Developments
Merger Agreement
As described in Note 1 — Description of Business, Basis of Presentation and Significant Accounting Policies and Note 14 – Merger Agreement, on March 7, 2024, the Company entered into the Merger Agreement with Parent and Merger Sub. Upon the terms and subject to the conditions provided in the Merger Agreement, and in accordance with the Delaware General Corporation Law (the “DGCL”), at the effective time of the Merger (the “Effective Time”), Merger Sub will merge with and into the Company, with the Company continuing as the surviving corporation. As a result of the Merger, the Company will cease to be a publicly traded company and will be wholly owned by the Parent.
At the Effective Time, by virtue of the occurrence of the Merger, the following will occur:
26
Following the execution of the Merger Agreement, and pursuant to the terms of the Merger Agreement, the Company deposited into a segregated bank account of Astra Space Operations LLC (the “Segregated Account”) an amount in cash equal to $3.5 million (the “Segregated Funds”). The Segregated Funds are managed by the Company at the reasonable direction of the Special Committee of the Board of Directors acting in accordance with its fiduciary duties. At the request of the Special Committee, the Company purchased on April 11, 2024 additional Directors and Officers insurance coverage at a cost of $937,500. Thus, reducing the total amount in the Segregated Account to $2.6 million.
All outstanding Convertible Notes will, immediately after the Merger becomes effective, be converted into shares of Series A preferred stock, par value $0.0001 per share, of Parent (the “Parent Series A Preferred Stock”) in accordance with a noteholder conversion agreement, by and among Parent, Merger Sub, and each holder of Convertible Notes (the “Noteholder Conversion Agreement”) at a conversion rate of $0.404. The Original Warrants and Company Warrants will, immediately after the Merger becomes effective, be exchanged for warrants to purchase Parent Series A Preferred Stock at an exercise price of $0.404 per share in accordance with a warrant exchange agreement, by and among Parent, Merger Sub, and each holder of Company Warrants. (the “Warrant Exchange Agreement”).
The execution and delivery of the Merger Agreement, subject to the requisite stockholder approval was recommended by the Special Committee to the Board on March 5, 2024. On March 5, 2024, the Board, with Mr. Kemp, Dr. London and Mr. Stanford abstaining, approved the execution and delivery of the Merger Agreement and recommended the adoption of the Merger Agreement and the Merger to the stockholders of the Company. On March 7, 2024, following the execution of the Merger Agreement, Mr. Kemp and Dr. London, who on such date beneficially owned Common Shares representing approximately 66.2% of the total voting power of the outstanding Common Shares, executed and delivered to the Company a Written Consent adopting the Merger Agreement and approving the Merger. No further action by any other Company stockholder is required under applicable law or the Merger Agreement (or otherwise) in connection with the adoption of the Merger Agreement and the Company is currently in the process of responding to comments from the SEC on its preliminary information statement on Schedule 14C (and related amendments) and related Rule 13e-3 Transaction Statement on Schedule 13E-3 (and related amendments). Once we resolve any outstanding comments from the SEC, we will file a definitive information statement and mail the information statement to holders of our Class A Common Stock. Subject to the satisfaction of closing conditions, we would expect to consummate the Merger some time after the delivery of the definitive information statement to holders of our Class A Common Stock.
Section 220 Demand in Connection with the Merger Agreement.
Following the announcement of the Merger Agreement, the Company has received demands to inspect the Company’s books and records pursuant to 8 Del. C. § 220 (“Section 220”). Specifically, on April 5, 2024, purported stockholder Jonathan Horner delivered a Section 220 demand to the Company, which demand was supplemented on April 11, 2024. On April 17, 2024, another purported stockholder, Michael Krene, represented by the same law firm, delivered a second Section 220 demand to the Company. On April 22, 2024, a third purported stockholder, Jerry Hamelton, delivered a Section 220 demand to the Company (collectively, the “Section 220 Demands”).
Although the specifics of each Section 220 Demand varies, they generally intend to investigate the events leading to execution of the Merger Agreement, to investigate the independence and disinterestedness of certain members of the Company’s board of directors and officers in connection with the Merger Agreement and the Merger, and to determine whether such directors and officers properly discharged their fiduciary duties, investigate the Company’s disclosures regarding the Merger Agreement and the Merger. The Section 220 Demands seek to inspect the Company’s books and records to determine whether wrongdoing, mismanagement, and/or material non-disclosure has taken place such that it would be appropriate to file an action against the Board, the officers, the Company, or any other relevant person or entity, to value each stockholder’s shares, and to consider any other courses of action that the investigation might warrant pursuing.
27
The Company is evaluating each of the Section 220 Demands and intends to defend vigorously any allegation of wrongdoing, mismanagement and/or non-disclosure. Due to the early stage of these investigations, neither the likelihood that a loss, if any, will be realized, nor an estimate of the possible loss or range of loss, if any, can be determined.
Subsequent Issuances of Convertible Notes and Company Warrants
Since December 31, 2023, the Company has closed on subsequent financings under the Subsequent Financing Agreement (as further amended or modified on January 19, 2024, January 31, 2024, February 26, 2024, March 7, 2024,April 10, 2024 and April 30, 2024) on January 19, 2024, February 26, 2024, March 5, 2024, March 7, 2024, March 8, 2024, March 15, 2024, April 22, 2024 and May 13, 2024. As of the date of this Quarterly Report, the aggregate principal amount of all outstanding Convertible Notes (including any paid-in-kind interest) was $37.8 million and there were Company Warrants (including warrants issued on August 4, 2023) outstanding to purchase 16,989,759 shares of Class A Common Stock at an exercise price of $0.808, subject to certain adjustments, and that expire on dates ranging from August 4, 2028 to May 13, 2029. The investors participating in the Subsequent Financings were the Kemp Trust, Dr. London, MH Orbit, LLC, an affiliate of JMCM, RBH Ventures Astra SPV, LLC, Astera Institute, ERAS Capital, LLC and Ulrich Gall.
AST License Agreement
On March 6, 2024, a subsidiary of the Company, entered into a Royalty Bearing Manufacturing License (the “Manufacturing License”) with Astra Space Technologies Holding, Inc ("AST"). The Company and AST are parties to a Supply and Manufacturing Agreement, dated April 28, 2022 (the “Supply Agreement”), pursuant to which the Company manufactures certain spacecraft engines, flight sets, power processing units and feed systems (the “AST Products”) for AST. The Manufacturing License, among other things, provides AST a license to manufacture the AST Products for its internal use as a means to increase the quantity of AST Products available in the future and to provide an alternative source of supply for a critical component. The Manufacturing License is a limited, non-exclusive, non-transferable, irrevocable, non-sublicensable, fully paid license to make and have made a specified number of AST Products. In consideration of the Manufacturing License, on March 6, 2024, AST paid the Company $2.5 million, representing the royalties due for the initial AST Products to be manufactured under the Manufacturing License. At AST’s option, AST will pay the Company, on a quarterly basis, additional royalties per AST Product manufactured during the prior quarter after the initial AST Products. In addition, on March 6, 2024, the Company and AST entered into an order addendum to the Supply Agreement pursuant to which AST purchased additional AST Products from the Company for a total of $1.05 million with $420,000 due in April 2024 and additional payments due in the second half of the year upon delivery of additional AST Products.
Consolidation of Operations at our Skyhawk Facility
Management has begun the process of consolidating its operations into its existing facility in Alameda, California (Skyhawk). As a result, management expects to relocate its employees and equipment from its facility in Sunnyvale, California to Skyhawk by the end of the third quarter of 2024.
Critical Accounting Estimates
Our financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. Preparation of the financial statements requires our management to make a number of judgments, estimates and assumptions relating to the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We consider an accounting judgment, estimate or assumption to be critical when (1) the estimate or assumption is complex in nature or requires a high degree of judgment and (2) the use of different judgments, estimates and assumptions could have a material impact on our consolidated financial statements. We have made no updates
28
or made additions to our significant accounting policies as described in Note 1 Description of Business, Basis of Presentation and Significant Accounting Policies in our 2023 Annual Report.
Results of Operations
Comparison of the three months ended March 31, 2024 and 2023
|
|
Three Months Ended |
|
|
Period over |
|
||||||||||
(in thousands, except percentages) |
|
2024 |
|
|
2023 |
|
|
($) |
|
|
(%) |
|
||||
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Launch services |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
NM |
|
|
Space products |
|
|
285 |
|
|
|
— |
|
|
|
285 |
|
|
|
100 |
% |
Total revenues |
|
|
285 |
|
|
|
— |
|
|
|
285 |
|
|
|
100 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Launch services |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
NM |
|
|
Space products |
|
|
128 |
|
|
|
— |
|
|
|
128 |
|
|
|
100 |
% |
Total cost of revenues |
|
|
128 |
|
|
|
— |
|
|
|
128 |
|
|
|
100 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Segment gross profit: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Launch services |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
NM |
|
|
Space products |
|
|
157 |
|
|
|
— |
|
|
|
157 |
|
|
|
100 |
% |
Total segment gross profit |
|
$ |
157 |
|
|
$ |
— |
|
|
$ |
157 |
|
|
|
100 |
% |
____________
n.m. = not meaningful.
Revenues
Launch Services
In August 2022, we discontinued the production of launch vehicles supported by our Launch System 1. Therefore, we did not conduct any commercial launches during the three months ended March 31, 2024 and 2023, as we shifted resources to the development of our Launch System 2.
We do not anticipate any revenues related to Launch Services in 2024 as we continue to work to develop and test the next version of our launch system: Rocket 4 (aka Launch System 2).
Space Products
Revenues of $0.3 million for the three months ended March 31, 2024, all of which were related to deliveries made to our Space Products customers. We had no Space Products revenues for the three months ended March 31, 2023.
Cost of Revenues
Cost of revenues consist primarily of direct material, direct labor, manufacturing overhead, other personnel-related expenses, which include salaries, bonuses, benefits, stock-based compensation expense, and depreciation expense. Cost of revenues also includes inventory write-downs to reduce the carrying value of inventory related to Launch Services when the carrying value exceeds its estimated net realizable value.
Launch Services
As with revenues, we do not anticipate any costs of revenues related to our Launch Services in 2024.
Space Products
Costs of revenues related to Space Products were $128.0 million for the three months ended March 31, 2024 and was primarily related to deliveries to our Space Products customers. We had no costs of revenues related to Space Products for the three months ended March 31, 2023.
29
Operating Expenses
|
|
Three Months Ended |
|
|
Period over |
|
||||||||||
(in thousands, except percentages) |
|
2024 |
|
|
2023 |
|
|
($) |
|
|
(%) |
|
||||
Segment gross profit |
|
$ |
157 |
|
|
$ |
- |
|
|
$ |
157 |
|
|
|
100 |
% |
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
12,641 |
|
|
|
31,082 |
|
|
|
(18,441 |
) |
|
|
59 |
% |
Sales and marketing |
|
|
865 |
|
|
|
2,484 |
|
|
|
(1,619 |
) |
|
|
65 |
% |
General and administrative |
|
|
11,036 |
|
|
|
15,682 |
|
|
|
(4,646 |
) |
|
|
30 |
% |
Gain on change in fair value of contingent consideration |
|
|
— |
|
|
|
(2,765 |
) |
|
|
2,765 |
|
|
|
100 |
% |
Total operating expenses |
|
|
24,542 |
|
|
|
46,483 |
|
|
|
(21,941 |
) |
|
|
47 |
% |
Operating loss |
|
|
(24,385 |
) |
|
|
(46,483 |
) |
|
|
22,098 |
|
|
|
48 |
% |
Interest income |
|
|
5 |
|
|
|
1,330 |
|
|
|
(1,325 |
) |
|
|
100 |
% |
Other income, net |
|
|
232 |
|
|
|
260 |
|
|
|
(28 |
) |
|
|
11 |
% |
Gain on change in fair value of Convertible Notes |
|
|
47,270 |
|
|
|
- |
|
|
|
47,270 |
|
|
|
0 |
% |
Gain on change in fair value of warrants |
|
|
15,007 |
|
|
|
— |
|
|
|
15,007 |
|
|
|
0 |
% |
Income (loss) before taxes |
|
|
38,129 |
|
|
|
(44,893 |
) |
|
|
83,022 |
|
|
|
185 |
% |
Provision for income tax |
|
|
— |
|
|
|
— |
|
|
|
- |
|
|
n.m. |
|
|
Net income (loss) |
|
$ |
38,129 |
|
|
$ |
(44,893 |
) |
|
$ |
83,022 |
|
|
|
185 |
% |
____________
n.m. = not meaningful.
Research and Development
Our R&D expenses consist primarily of internal and external expenses incurred in connection with our research activities and development programs. These expenses include, but are not limited to, development supplies, testing materials, personnel and personnel-related costs (including salaries, bonuses, benefits, and stock-based compensation expense), depreciation expense, amortization of intangible assets, overhead allocation (consisting of various support and facility costs), and consulting fees. R&D costs are expensed as incurred. We allocate R&D costs by function rather than by project, as a significant majority of our historical R&D spending was related to the initial development and testing of our underlying technology, including preparation for multiple test launches. A change in the outcome of any of these variables could delay the development of our launch systems and Space Products, which in turn could impact the timing of commercialization of our offerings.
R&D costs were $12.6 million and $31.1 million for the three months ended March 31, 2024 and 2023, respectively. The $18.5 million decrease mainly reflected an $8.7 million reduction in expensed R&D equipment, a $7.0 million decrease in personnel-related costs due to lower headcount in R&D departments, a $1.2 million reduction in stock-based compensation, a $0.9 million reduction in licensed technology, a $0.5 million reduction in professional services, a $0.4 million reduction in depreciation and amortization and a $0.1 million reduction of other R&D costs, partially offset by a $0.3 million increase in facilities costs.
Sales and Marketing
Sales and marketing expenses consist of personnel and personnel-related expenses (including stock-based compensation expense) for our business development team as well as advertising and marketing expenses. We expect to increase our sales and marketing activities in order to grow our customer base and increase market share in the future.
Sales and marketing expenses were $0.9 million and $2.5 million for the three months ended March 31, 2024 and 2023, respectively. The $1.6 million decrease mainly reflected a $1.3 million reduction in personnel-related costs and $0.3 million reduction in other sales and marketing costs.
General and Administrative
General and administrative expenses consist primarily of personnel and personnel-related costs (including salaries, bonuses, benefits, and stock-based compensation expense) for personnel in executive, finance, accounting, corporate development and other administrative functions. General and administrative expenses also include legal fees, professional fees paid for accounting, auditing, consulting, tax, and investor relations services, insurance costs, facility costs not otherwise included in R&D expenses and costs associated with compliance with the rules and regulations of the SEC and the stock exchange.
General and administrative expenses were $11.0 million and $15.7 million for the three months ended March 31, 2024 and 2023, respectively. The $4.7 million decrease was primarily due to a $4.5 million reduction in personnel-related costs, a $1.1 million reduction in facilities costs, a $0.6 million reduction in insurance costs, a $0.6 million reduction in stock-based compensation and a $0.2 million reduction in R&D materials expense, partially offset by a $1.0 million increase in professional services, a $0.7 million increase in licensed technology costs, a $0.3 million increase in other general and administrative expenses primarily related to strategic financing costs and a $0.3 million increase in depreciation expense.
30
Loss on Change in Fair Value of Contingent Consideration
We settled our contingent consideration obligation during the fourth quarter of 2023 and have no remaining obligation in 2024. The loss on change in fair value of contingent consideration of $2.8 million during the three months ended March 31, 2023 was primarily the result of lower revenues than those used to forecast our estimates of the fair value of contingent consideration.
Interest Income
Interest income for the three months ended March 31, 2024 was insignificant as compared to $1.3 million for the three months ended March 31, 2023. The $1.3 million in interest income in the prior year's quarter was primarily due to interest income earned on securities held prior to liquidation of our marketable securities portfolio in the third quarter of 2023.
Other Income/(Expense), Net
Other income (expense), net primarily consists of income from government research and development contracts.
Other income, net was $0.2 million for the three months ended March 31, 2024 and is comparable to $0.3 million for the three months ended March 31, 2023.
Gain on Change in Fair Value of Warrant Liabilities
As of March 31, 2024, we had 14,823,917 Company Warrants issued and outstanding, including warrants issued on August 4, 2023, all of which were issued concurrently with financing transactions, including the sale and issuance of the Convertible Notes, during the year ended December 31, 2023 and the three months ended March 31, 2024. The Company Warrants are recorded at fair value each reporting date and any changes in fair value during the reporting period are recognized in the consolidated statements of operations. As of March 31, 2024, the aggregate fair value of the Company Warrants was $5.8 million and we recognized a gain of $15.0 million during the three months ended March 31, 2024 due to the change in fair value of the Company Warrants.
Gain on Change in Fair Value of Convertible Notes
We have elected the fair value option to account for our Convertible Notes and, therefore, any changes in fair value during the reporting period are recognized in the consolidated statements of operations. As of March 31, 2024, the aggregate fair value of our Convertible Notes was $28.2 million. During the three months ended March 31, 2024, we recognized a gain of $47.3 million related to the change in fair value of our Convertible Notes, which resulted primarily from our understanding from discussions with the Parent and related filings of affiliates of the Parent that, pursuant to the noteholder conversion agreements entered into with the holders of the Convertible Notes and the Parent, the Convertible Notes will be converted into shares of Series A Preferred Stock of the Parent at a conversion rate of $0.404 upon the consummation of the Merger.
Provision for Income Tax
Our provision for income tax consists of an estimate for U.S. federal and state income taxes based on enacted rates, as adjusted for allowable credits, deductions, uncertain tax positions, changes in deferred tax assets and liabilities, and changes in the tax law. We maintain a valuation allowance against the full value of our U.S. and state net deferred tax assets because we believe the recoverability of the tax assets is not more likely than not.
We did not incur income tax expense for the three months ended March 31, 2024 and 2023.
Liquidity and Capital Resources
As of March 31, 2024, the Company’s existing sources of liquidity are cash and cash equivalents of $6.6 million, which includes $3.5 million in funds that are required to be set aside in a segregated account under the terms of the Merger Agreement and used only for specified purposes, and restricted cash of $0.5 million related to a letter of credit issued to secure our performance obligations under a customer contract. We cannot access this restricted cash until we have begun delivery of flight sets for this customer’s program, which is expected to be in November 2024 pursuant to the contract schedule.
The Company believes that its current level of cash and cash equivalents is not sufficient to fund commercial scale production and sale of its services and products. Since December 31, 2023, through the date of this Quarterly Report, the Company has raised gross proceeds of approximately $19.9 million through the sale of Convertible Notes and Company Warrants, exercisable into 7,793,132 shares of the Company’s Class A Common Stock. Notwithstanding the proceeds raised from the issuance of these additional Convertible Notes and Company Warrants, the Company expects it will need to continue to raise substantial additional funds through the issuance of additional debt, equity or both in order to execute on its business plan and continue its business operations through to the closing of the Merger Agreement.
Under the terms of the Merger Agreement, the Company is restricted from incurring new debt or issuing equity except through the offer and sale of the Convertible Notes and Company Warrants. The Merger Agreement further prohibits the Company from issuing Convertible Notes or Company Warrants to any person prior to the consummation of the Merger unless (i) such person becomes a noteholder under the Noteholder Conversion Agreement or a holder under the Warrant Exchange Agreement as described in,
31
respectively, by executing a joinder agreement substantially in the form attached to such agreement and delivering the same to each of Merger Sub and Parent and (ii) holders of a majority in interest of the Convertible Notes or Company Warrants, as applicable, then outstanding consent to such issuance and joinder, all of which may affect the Company’s ability to raise additional funds from the sale of its Convertible Notes and Company Warrants on the timing needed. If the Company is unable to obtain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. The Company may be required to delay, limit, reduce or terminate its product development activities or future commercialization efforts or cease business operations, including through a petition for voluntary relief under Chapter 7 of the United States Bankruptcy Code (a “Chapter 7 Liquidation”).
At various points during the second half of 2023 and thus far in 2024, the Company has considered and even begun preparations to file for voluntary relief under either Chapter 11 or Chapter 7 of the Bankruptcy Code because the Company faced an inability to fund its ongoing operations.
As a result of these uncertainties, and notwithstanding management’s plans and efforts to date, there is substantial doubt about the Company’s ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements. If the Company is unable to raise substantial additional capital in the near term and as necessary to continue the Company’s business operation to a closing of the Merger, the Company's operations and production plans will be further scaled back or curtailed and the Company may be required to file a Chapter 7 Liquidation. If the funds raised are insufficient to provide a bridge to the closing of the Merger, or, in the case of a termination of the Merger Agreement, full commercial production at a profit, the Company's operations could be severely curtailed or cease entirely and the Company may be required to file a Chapter 7 Liquidation and in such case, may not realize any significant value from the liquidation of its assets.
Summary Statement of Cash Flows for the Three Months Ended March 31, 2024 and 2023
The following table sets forth the primary sources and uses of cash and cash equivalents for the periods presented below:
|
|
Three Months Ended |
|
|
Period over |
|
||||||||||
(in thousands) |
|
2024 |
|
|
2023 |
|
|
$ |
|
|
% |
|
||||
Net cash used in operating activities |
|
$ |
(12,593 |
) |
|
$ |
(35,999 |
) |
|
$ |
23,406 |
|
|
|
(65 |
)% |
Net cash provided by (used in) investing activities |
|
|
(33 |
) |
|
|
18,719 |
|
|
|
(18,752 |
) |
|
|
(100 |
) |
Net cash provided by financing activities |
|
|
14,302 |
|
|
|
441 |
|
|
|
13,861 |
|
|
|
3,143 |
|
Net decrease in cash and cash equivalents |
|
$ |
1,676 |
|
|
$ |
(16,839 |
) |
|
$ |
18,515 |
|
|
|
(110 |
)% |
Cash Flows from Operating Activities
Our cash flows from operating activities are significantly affected by our cash expenditures to support the growth of our business in areas such as research and development and general and administrative and working capital. Our operating cash inflows include cash from milestone billing under certain Space Products contracts in 2023 and Launch Services contracts in 2022. These cash inflows are offset by our payments to suppliers for production materials and parts used in our manufacturing process as we ramp up our production for space products, payments to our employees and other operating expenses.
For the three months ended March 31, 2024, net cash used in operating activities was $12.6 million. The primary factors affecting our operating cash flows during the period were a net income of $38.1 million and non-cash charges of $56.3 million including a gain on change in fair value of Convertible Notes of $47.3 million, a gain on change in fair value of warrants of $15.0 million, partially offset by stock-based compensation expense of $3.5 million, depreciation and amortization expense of $1.7 million, an increase in non-cash lease expense of $0.8 million. Changes in operating working capital items were mainly due to an increase in contract liabilities of $9.2 million, an increase in accounts payable of $0.6 million and in prepaid and other current assets of $0.4 million. These increases were partially offset by a decrease in accrued expenses and other current liabilities of $2.0 million, a decrease in inventories of $1.5 million, a decrease in lease liabilities of $0.8 million and a decrease in trade accounts receivable of $0.5 million.
For the three months ended March 31, 2023, net cash used in operating activities was $36.0 million. The primary factors affecting our operating cash flows during the period were a net loss of $44.9 million. This is offset by non-cash charges of $4.4 million including stock-based compensation expense of $5.3 million, depreciation and amortization expense of $1.3 million and non-cash lease expense of $0.9 million, partially offset by a gain on change in fair value of contingent consideration of $2.8 million. Changes in operating working capital items are mainly due to an increase in accounts payable of $7.0 million, partially offset by a decrease in trade accounts receivable of $1.5 million and a decrease in prepaid and other current assets of $1.4 million.
Cash Flows from Investing Activities
For the three months ended March 31, 2024, net cash used in investing activities was $33.0 thousand, which was comprised mainly of purchases of property, plant and equipment related to leasehold improvements at our corporate headquarters in Alameda, California.
32
For the three months ended March 31, 2023, net cash used in investing activities was $18.7 million, which was comprised mainly of maturities of marketable securities of $23.8 million, partially offset by $5.0 million of purchases of property, plant and equipment related to leasehold improvements at our Sunnyvale manufacturing facility and corporate headquarters in Alameda, California.
Cash Flows from Financing Activities
For the three months ended March 31, 2024, net cash provided by financing activities of $14.3 million was comprised of $12.0 million proceeds from the sale of Convertible Notes and $2.3 million proceeds from the issuance of Company Warrants and the issuance of Class A Common Stock under our equity plans.
For the three months ended March 31, 2023, net cash provided by financing activities amounted to $0.4 million and consisted of proceeds from the issuance of shares of Class A common stock under equity plans.
Compliance with the Continued Listing Standards of the Nasdaq Capital Market (“Nasdaq”)
We are not in compliance with Rules 5450(a)(1), 5550(b)(1) and 5250(c)(1) of the listing requirements. We received written notice from Nasdaq of the listing of our failure to be in compliance with Rule 5450(a)(1) of the listing requirements (the "Minimum Bid Price Requirement") on April 17, 2024. On April 23, 2024, we received written notice from Nasdaq of our failure to be in compliance with Rule 5550(b)(1) of the listing requirements (the “Minimum Stockholders’ Equity Requirement”). On May 22, 2024, we received written notice from Nasdaq that, due to our failure to timely file this Quarterly Report, we no longer comply with Nasdaq’s Listing Rules as set forth under Rule 5250(c)(1) (the “Timely Filing Requirement”).
These notices of noncompliance have no immediate impact on the continued listing or trading of the Company’s Class A Common Stock, which will continue to be listed and traded on Nasdaq, subject to the Company’s compliance with the other continued listing requirements.
With respect to the Minimum Bid Price Requirement, the Company has 180 calendar days, or until October 14, 2024, to regain compliance with the Minimum Bid Price Requirement. Nasdaq’s notice stated that if, at any time before October 14, 2024, the per share closing bid price of the Company’s Class A Common Stock is at least $1.00 for a minimum of ten consecutive business days, Nasdaq’s staff will provide the Company written notice that it complies with the Minimum Bid Price Requirement. If the Company does not regain compliance with the Minimum Bid Price Requirement by October 14, 2024, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, Astra would need to, among other things, meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for NASDAQ, with the exception of the Minimum Bid Price Requirement, and provide written notice to Nasdaq that it intends to cure the deficiency during the second compliance period. If Nasdaq concludes that the Company will not be able to cure the deficiency during the second compliance period, or the Company does not make the required representations, then Nasdaq will give notice that Astra’s Class A Common Stock is subject to delisting and Astra will be able to appeal that delisting before a Nasdaq hearings panel.
With respect to the Minimum Stockholders’ Equity Requirement, the Company has 45 calendar days, or until June 7, 2024, to submit a plan to regain compliance with the Minimum Stockholders’ Equity Requirement. If the Company’s plan is accepted, the Company may be granted 180 additional calendar days from April 23, 2024, or until October 20, 2024, to evidence compliance with the Minimum Stockholders’ Equity Requirement. In the event the plan to regain compliance with the Minimum Stockholders’ Equity Requirement is not accepted by Nasdaq, or, in the event a plan is accepted and an extension period is granted but Company fails to regain compliance within that period, the Class A Common Stock will be subject to delisting. The Company would have the right to appeal that decision before a Nasdaq hearing panel. The hearing request would stay any suspension or delisting action pending the conclusion of the hearing process and the expiration of any additional extension period granted by the panel following the hearing.
With respect to the Timely Filing Requirement, we have until July 22, 2024, to submit to Nasdaq a plan to regain compliance with the Timely Filing Requirement. If Nasdaq accepts the plan, Nasdaq may grant up to an additional 180 calendar days or until November 18, 2024, to regain compliance.
There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement or the Minimum Stockholders’ Equity Requirement, that it will be granted an exception to the Timely Filing Requirement or that it will otherwise remain in compliance with the other listing requirements for Nasdaq.
As discussed earlier in this report, the Company entered into a Merger Agreement on March 7, 2024, if the Merger is consummated, the Company’s Class A Common Stock will be delisted from the Nasdaq Capital Market in connection with the consummation of the Merger.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We have not, to date, been exposed to material market risks given our early stage of operations. As we expand our commercial operations, we expect to be exposed to foreign currency exchange rate and commodity price risks, particularly related to rocket
33
propellants, helium, and aluminum, among others, and potentially other market risks, including those related to interest rates or valuation of financial instruments, among others. There were no material changes in our market risk since the year ended December 31, 2023.
Item 4. Controls and Procedures
Evaluation of disclosure controls and procedures
We maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, who serves as our principal executive officer, and Chief Financial Officer, who serves as our principal financial officer, as appropriate, to allow for timely decisions regarding required disclosures. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of March 31, 2024, due to the material weaknesses in our internal control over financial reporting described below.
Material Weaknesses in Internal Control over Financial Reporting
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Specifically, material weaknesses identified are:
Control Environment
We did not design and maintain an effective control environment to enable the identification and mitigation of risks of material misstatement which contributed to the following material weaknesses:
Risk Assessment
We did not design and maintain controls over an effective risk assessment, including: (i) identifying, assessing, and communicating appropriate objectives, (ii) identifying and analyzing risks to achieve these objectives, and (iii) identifying and assessing changes in the business that could impact our internal control over financial reporting.
Control Activities
We did not design and maintain effective control activities as the control activities did not adequately (i) address relevant risks, (ii) provide evidence of performance, (iii) provide appropriate segregation of duties, or (iv) operate at a sufficient level of precision.
Information and Communication
34
We did not design and maintain controls over information and communication relating to communicating accurate information internally and externally, including providing information pursuant to objectives, responsibilities, and functions of internal control.
Monitoring Activities
We did not design and maintain effective monitoring controls to ascertain whether the components of internal control are present and functioning.
These material weaknesses resulted in audit adjustments and immaterial errors to our accounts and disclosures, as of and for the years ended December 31, 2023 and 2022.
Additionally, these material weaknesses could result in a misstatement of substantially all of our account balances or disclosures that would result in a material misstatement to the annual or interim consolidated financial statements that would not be prevented or detected.
Remediation Plan
Through the year ended December 31, 2023, our executive management team, including our Chief Executive Officer and Chief Financial Officer, continued to work to design and implement both a short-term and a long-term remediation plan to correct the material weaknesses in our internal control over financial reporting as described below. We were focused on enhancing the design and implementation of effective internal control measures to improve our internal control over financial reporting and remediate these material weaknesses.
This included the following areas to address the material weaknesses, and management had completed, or were in the process of completing:
During the first quarter of 2024, while the Company continued to operate, and make improvements in our control environment, our primary focus has been to maintain the existing controls and processes.
Changes in Internal Control over Financial Reporting
35
There have been no changes in our internal control over financial reporting (as that term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
36
PART II—OTHER INFORMATION
Item 1. Legal Proceedings
Discussion of legal matters is incorporated by reference from Part I, Item 1, Note 8- Commitments and Contingencies, of this Quarterly Report on Form 10-Q, and should be considered an integral part of Part II, Item 1, “Legal Proceedings.”
Item 1A. Risk Factors
There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the period ended December 31, 2023, filed with the SEC on April 18, 2024.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
None.
Item 5. Other Information
No director or Section 16 officer of the Company
37
Item 6. Exhibits
|
|
|
|
Incorporated by Reference |
||||||
Exhibit Number |
|
Description |
|
Form |
|
SEC File No. |
|
Exhibit |
|
Filing Date |
4.1 |
|
|
8-K |
|
001-39426 |
|
4.2 |
|
November 24, 2023 |
|
4.2 |
|
|
8-K |
|
001-39426 |
|
4.1 |
|
February 6, 2024 |
|
4.3 |
|
|
8-K |
|
001-39426 |
|
4.1 |
|
March 1, 2024 |
|
4.4 |
|
|
8-K |
|
001-39426 |
|
4.1 |
|
April 15, 2024 |
|
4.5 |
|
|
8-K |
|
001-39426 |
|
4.1 |
|
May 1, 2024 |
|
4.6 |
|
|
10-K |
|
001-39426 |
|
4.2 |
|
March 30, 2023 |
|
10.1 |
|
|
8-K |
|
001-39426 |
|
10.1 |
|
August 4, 2023 |
|
10.2 |
|
|
8-K |
|
001-39426 |
|
10.1 |
|
November 24, 2023 |
|
10.3 |
|
|
8-K |
|
001-39426 |
|
10.1 |
|
January 25, 2024 |
|
10.4 |
|
|
10-K |
|
001-39426 |
|
10.29 |
|
April 18, 2024 |
|
10.5 |
|
|
8-K |
|
001-39426 |
|
10.1 |
|
February 6, 2024 |
|
10.6 |
|
|
8-K |
|
001-39426 |
|
10.1 |
|
March 1, 2024 |
|
10.7 |
|
|
8-K |
|
001-39426 |
|
10.1 |
|
March 12, 2024 |
|
10.8 |
|
|
10-K |
|
001-39426 |
|
10.34 |
|
April 18, 2024 |
|
10.9 |
|
|
8-K |
|
001-39426 |
|
10.1 |
|
April 15, 2024 |
38
10.10 |
|
|
8-K |
|
001-39426 |
|
10.1 |
|
May 1, 2024 |
|
31.1* |
|
|
|
|
|
|
|
|
|
|
31.2* |
|
|
|
|
|
|
|
|
|
|
32.1** |
|
|
|
|
|
|
|
|
|
|
32.2** |
|
|
|
|
|
|
|
|
|
|
101.INS |
|
Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. |
|
|
|
|
|
|
|
|
101.SCH |
|
Inline XBRL Taxonomy Extension Schema Document |
|
|
|
|
|
|
|
|
101.CAL |
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document |
|
|
|
|
|
|
|
|
101.DEF |
|
Inline XBRL Taxonomy Extension Definition Linkbase Document |
|
|
|
|
|
|
|
|
101.LAB |
|
Inline XBRL Taxonomy Extension Label Linkbase Document |
|
|
|
|
|
|
|
|
101.PRE |
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document |
|
|
|
|
|
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
|
|
|
|
|
|
|
|
* Filed herewith.
** Furnished herewith.
39
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
Astra Space, Inc. |
|
|
|
|
|
Date: May 28, 2024 |
|
By: |
/s/ Chris C. Kemp |
|
|
|
Chris C. Kemp |
|
|
|
Chief Executive Officer and Chairman of Board and Principal Executive Officer |
|
|
|
|
Date: May 28, 2024 |
|
By: |
/s/ Axel Martinez |
|
|
|
Axel Martinez |
|
|
|
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
40